Enterotoxin tilimycin from gut-resident Klebsiella promotes mutational evolution and antibiotic resistance in mice

Sabine Kienesberger1,2,3, Amar Cosic1, Maksym Kitsera1

  • 1Institute of Molecular Biosciences, University of Graz, Graz, Austria.

Nature Microbiology
|October 27, 2022
PubMed

Insights

The bacterial toxin tilimycin, secreted by Klebsiella, acts as a mutagen in the gut. This genotoxin promotes antibiotic resistance and disrupts the gut microbiota composition and stability.

Area of Science:

  • Microbiology
  • Genetics
  • Gut Microbiome Research

Background:

  • Klebsiella spp. colonize the human gut and secrete the DNA-alkylating enterotoxin tilimycin.
  • Antibiotic use increases toxigenic bacteria, leading to tilimycin accumulation and gut epithelial damage via genetic instability and apoptosis.

Purpose of the Study:

  • To investigate the impact of the genotoxin tilimycin on the gut ecosystem.
  • To understand tilimycin's role as a pro-mutagenic agent and its effects on microbial communities.

Main Methods:

  • 16S rRNA sequencing of faecal samples from colonized mice.
  • Mechanistic analyses to determine tilimycin's effects on microbial populations and mutagenesis.

Main Results:

  • Tilimycin was identified as a pro-mutagenic antibiotic affecting multiple bacterial phyla.
  • Transient tilimycin synthesis reduced microbial richness, altered taxonomic composition, and antagonized niche competitors.
  • Tilimycin secretion accelerated mutagenesis in opportunistic pathogens, leading to de novo antibiotic resistance acquisition.

Conclusions:

  • Tilimycin functions as a bacterial mutagen.
  • Genotoxic Klebsiella flares can drive antibiotic resistance emergence.
  • Tilimycin has the potential to destabilize the gut microbiota and influence its evolutionary path.